Massachusetts Institute of Technology

Children's Medical Center Corporation

Boston University

Children's Medical Center Coporation

Arturo Jose Vegas

Daniel Griffith Anderson

Robert Samuel Langer

Minglin Ma

Omid Veiseh

Joshua C Doloff

Delai Chen

Yunlong Zhang

Kaitlin M Bratlie

Christian J Kastrup

Robert S Langer

Yi Heng Chen

Kevin Thomas Love

Yizhou Dong

Akinleye C Alabi

Joseph R Dorkin

Kathryn Ann Whitehead

Joshua Charles Doloff

Rosemary Lynn Kanasty

Robert S Langer, Jr

Angela N Koehler

Shelby Doyle

Becky Leifer

Benjamin C Tang

Hung-Chieh Chou

Michael J Webber

Yair Levi

Daniel Sheehy

Kelly Tan

Volkan Yesilyurt

Stephen Thomas Nestor

Luke Ceo

Sean Quinnell

Akinleye Alabi

Yi Chen

Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for the encapsulation and transplantation of cells. Also disclosed are high throughput methods for the characterizing the biocompatibility and physiochemical properties of modified alginate polymers.

Modified alginates for cell encapsulation and cell therapy

Products, such as devices, prostheses, and materials, whose surfaces have been modified in order to impart beneficial properties to these products are disclosed. The surface-modified products have improved biocompatibility compared to a corresponding product that lacks the modification. Following implantation in a subject, the surface-modified products induce a lower foreign-body response, compared to a corresponding unmodified product.

Materials with improved biocompatibility

Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for coating of any material where reduced fibrosis is desired, such as encapsulated cells for transplantation and medical devices implanted or used in the body.

Modified alginates for anti-fibrotic materials and applications

The technology described herein is directed to IL-4 and/or IL-13 inhibitors and uses thereof.

Small molecule inhibitors of Interleukin-4

Described herein are compounds and compositions characterized, in certain embodiments, by conjugation of various groups, such as lipophilic groups, to an amino or amide group of an amino acid, a linear or cyclic peptide, a linear or cyclic polypeptide, or structural isomer thereof, to provide compounds of the present invention, collectively referred to herein as 'APPLs'. Such APPLs are deemed useful for a variety of applications, such as, for example, improved nucleotide delivery. Exemplary APPLs include, but are not limited to, compounds of Formula (I), (II), (III), (IV), (V), and (VI), and salts thereof, as described herein: wherein m, n, p, R', R, R, R, R, R, R, Z, W, Y, and Z are as defined herein.

Amino acid-, peptide- and polypeptide-lipids, isomers, compositions, and uses thereof

Biomedical devices for implantation with decreased pericapsular fibrotic overgrowth are disclosed. The device includes biocompatible materials and has specific characteristics that allow the device to elicit less of a fibrotic reaction after implantation than the same device lacking one or more of these characteristic that are present on the device. Biocompatible hydrogel capsules encapsulating mammalian cells having a diameter of greater than 1 mm, and optionally a cell free core, are disclosed which have reduced fibrotic overgrowth after implantation in a subject. Methods of treating a disease in a subject are also disclosed that involve administering a therapeutically effective amount of the disclosed encapsulated cells to the subject.

Multi-layer hydrogel capsules for encapsulation of cells and cell aggregates

Biocompatible hydrogel capsules encapsulating mammalian cells having a diameter of greater than 1 mm, and optionally a cell free core, are disclosed which have reduced fibrotic overgrowth after implantation in a subject. Methods of treating a disease in a subject are also disclosed that involve administering a therapeutically effective amount of the disclosed encapsulated cells to the subject.

Zwitterionic polymers or biocompatible polymers with improved properties for cell encapsulation, coating of devices, or a combination thereof are described. The biocompatible polymer contains a zwitterionic monomer, a monomer with a reactive side chain, and optionally another hydrophobic monomer or a neutral hydrophilic monomer. The zwitterionic polymers are cross-linked with a cross-linker via covalent bond to form a zwitterionic hydrogel in the presence of cells. Also provided, are methods of making and using the zwitterionic polymers.

Biocompatible coatings and hydrogels for reducing foreign body response and fibrosis

Growing community of inventors

Belmont, MA, United States of America

Arturo Jose Vegas